predictive value (LR w 2 (3) = 12.75, P = 0.005), which seemed to be due, in large part, to the interaction of OPRM1 and CREB1 rs2551640 (P = 0.05). Among cases with an OPRM1 G allele, CREB1 rs2551640 genotype had little effect on the difference in nicotine reinforcement between NTX and placebo. Among cases homozygous for the OPRM1 A allele, those with CREB1 rs2551640 A/A genotypes took 74% of puffs from the nicotine cigarette in the NTX session and 82% in the placebo session. For those with CREB1 A/G or G/G genotypes, the direction of the treatment effect was reversed, with 83% nicotine puffs taken during NTX vs 73% during placebo.
Tourette syndrome is thought to be of polygenic aetiology. Decreased concentrations of serotonin (5-HT) and its metabolite, 5-hydroxyindole acetic acid (5-HIAA), in brain and cerebrospinal fluid of Tourette patients led us to speculate that 5-HT synthesis might be implicated in the pathogenesis of the disorder. We therefore focussed on the novel enzyme responsible for 5-HT synthesis in the brain, tryptophan hydroxylase 2 (TPH2). Our findings indicate an important role of genetic variation of TPH2 in the pathogenesis of Tourette syndrome.
Tourette syndrome is a complex neuropsychiatric disorder, which is characterized by chronic motor tics and at least one phonic tic. An increasing body of evidence points to an involvement of the serotonergic system in the pathophysiology of Tourette syndrome. Thus, serotonin (5-hydroxytryptamine; 5-HT) concentrations are decreased in subcortical brain regions in this disorder. 1 Similarly, levels of the 5-HT metabolite 5-HIAA are reduced in these brain regions 1 and in cerebrospinal fluid of Tourette syndrome patients. 2 This allowed us to speculate that 5-HT synthesis might be implicated in the pathogenesis of Tourette syndrome. We therefore investigated the enzyme responsible for 5-HT synthesis in the brain, TPH2. We assessed two variants of TPH2, including a functional variant, in patients with Tourette syndrome. Our study sample consisted of 98 unrelated patients with Tourette syndrome. All patients were recruited from the Outpatient TS Clinic of Hannover Medical School (MHH) and examined personally by one of the authors (KRMV). All procedures were performed in accordance with the guidelines of the MHH Institutional Review Board. Control DNA samples were obtained from 178 healthy controls. All patients and controls were of German descent, according to their names and phenotypic appearance. Genomic DNA was extracted from EDTAanticoagulated whole blood using QIAamp DNA Mini kits.
We assessed two single nucleotide polymorphisms (SNPs) of TPH2 located in and close to the transcriptional control region of the gene. SNP rs4570625 is located in the transcriptional control region of TPH2, at position À703 with respect to the transcription start site ( þ 1). SNP rs4565946 is located in intron 2 of TPH2. Genotyping of the SNPs was performed as described previously. 3, 4 Statistical evaluations on allelic and genotypic distributions were performed using the SPSS package version 13.0 (SPSS Inc., Chicago, IL, USA). Bonferroni correction was used to adjust for multiple testing. Haplotype analysis and testing for Hardy-Weinberg equilibrium was performed using HPlus v2.5.
An association with Tourette syndrome was seen for the CC genotype as well as the C allele of the intronic SNP rs4565946 (Table 1 ). In contrast, no association with Tourette syndrome was detected for the variant located in the promoter region (SNP rs4570625), which has previously been shown to be functional in imaging studies. 4, 5 Upon haplotype construction of both SNPs (rs4570625-rs4565946), we observed an association of the G-C haplotype and to a lesser extent, the T-C haplotype with Tourette syndrome (Table 1 ). To the best of our knowledge, it has not been investigated to date whether the intronic variant (SNP rs4565946) has any functional effects. Considering the significant association of Tourette syndrome with the G-C and T-C haplotypes, the given results for each single SNP and the observation that the T allele located in intron 2 is in complete linkage disequilibrium with the functional G allele of the promoter SNP, we assume that the intronic variant may also be functionally important. Alternatively, another hitherto unknown functional variant, which should be in linkage disequilibrium with the two investigated SNPs, is involved in the genetic predisposition to Tourette syndrome. Taken together, our findings indicate a pathogenetic role of variation of TPH2 in the development of Tourette syndrome.
Previous studies of serotonergic genes in Tourette syndrome have mostly yielded negative results. These studies have investigated the promoter polymorphism of the serotonin transporter (5-HTTLPR) 6 and the 5-HT3 receptor. 7 Regarding the 5-HT1A receptor, a missense mutation leading to an amino acid exchange (A219L) was identified in one patient with Tourette syndrome. 8 However, no further evidence for an involvement of the corresponding gene has been published to date.
In contrast to the previous negative findings in the 5-HTTLPR and the 5-HT3 receptor, it may therefore be the synthesis of 5-HT in the brain via TPH2 which exerts its influence on Tourette syndrome risk. Our finding suggests TPH2 as a plausible susceptibility gene for Tourette syndrome.
In summary, this is the first study to assess whether polymorphic variants of TPH2 are associated with Tourette syndrome. The results link TPH2 variations a Bonferroni-corrected P-values. Differences in allele frequencies between patients and controls were tested using a w 2 test. Differences in the number of genotypes between patients and controls with regard to SNPs rs4570625 and rs4565946 were assessed by comparing the numbers of each line with the added numbers of both other lines using a w 2 test. Haplotype analysis was performed using HPlus v2.5 (http://qge.fhcrc.org/hplus/). Haplotypes are composed of SNPs rs4570625 (first nucleotide) and rs4565946 (second nucleotide). No T-T haplotype was observed. The T allele of SNP rs4565946 was in complete linkage disequilibrium with the G allele of SNP rs4570625. OR (odds ratio) refer to the variant (T) alleles, the added genotypes, or the reference haplotype, respectively (CI, confidence interval). Statistically significant differences are given in bold.
